ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition

Reuters

Aug 15

ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition

ESSA Pharma Inc. has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a "due bill" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52022) on August 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559182964"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559182964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559182964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559182964","market":"us","top_or_hot":-1,"title":"ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a \"due bill\" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52022) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-15 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a \"due bill\" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52022) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPIX","symbol_name":"ESSA Pharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLb9HYJL:1","article_id":"2559182964","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559182964","pubTimestamp":1755203532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a \"due bill\" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPIX":"ESSA Pharma Inc.","BK4139":"生物科技"},"translate_title":"ESSA Pharma在业务清盘和XenoTherapeutics收购期间宣布除息日","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPIX":0.9},"content_text":"ESSA Pharma Announces Ex-Dividend Date Amidst Business Wind-Up and XenoTherapeutics Acquisition\n    \n\nESSA Pharma Inc. has announced significant developments in its restructuring process, including a return of capital distribution worth $80 million to its shareholders. This move is part of the company's winding-up process following a transaction with XenoTherapeutics, Inc., a non-profit biotechnology company, which will acquire all of ESSA's outstanding common shares. The distribution is set to be paid on August 22, 2025, with shareholders receiving roughly $1.69 per share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented a \"due bill\" trading period from August 19 to August 25, 2025. During this time, shares traded will include the right to the distribution, impacting sellers who will not receive the distribution if they sell during this period. Shareholders and potential buyers are advised to consult with their brokers to understand the implications of these trading procedures.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY52022) on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}